OncoMatch/Clinical Trials/NCT04921527
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Is NCT04921527 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including chiauranib and Paclitaxel for ovarian cancer.
Treatment: chiauranib · Paclitaxel — This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
platinum refractory or platinum resistant ovarian cancer
Cannot have received: VEGF/VEGFR inhibitor (Apatinib, Anlotinib, Fruquintinib, Bevacizumab)
Patients received vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR) inhibitor, like Apatinib, Anlotinib, Fruquintinib, Bevacizumab, etc.
Cannot have received: Aurora kinase inhibitor
Patients received ... Aurora kinase inhibitors.
Cannot have received: taxane (paclitaxel)
Exception: weekly schedule
Patients received weekly paclitaxel therapy.
Cannot have received: biological therapy
Biological therapy ... within 28 days prior to the first dose of study drug.
Cannot have received: immunotherapy
immunotherapy ... within 28 days prior to the first dose of study drug.
Cannot have received: hormonal therapy
hormonal therapy within 28 days prior to the first dose of study drug.
Cannot have received: investigational agent/instrument
Treatment with an investigational agent/instrument within 28 days prior to first dose of study drug.
Lab requirements
Blood counts
hemoglobin (Hb) ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10^9/L; platelets ≥90×10^9/L
Kidney function
serum creatinine <1.5×ULN
Liver function
total bilirubin <1.5×ULN; ALT, AST ≤2.5×ULN (≤5×ULN if liver involved)
Laboratory criteria are as follows: Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×10^9/L ; platelets ≥90×10^9/L; Biochemistry test: serum creatinine(cr) <1.5×ULN; total bilirubin<1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≤2.5×ULN; (ALT,AST≤5×ULN if liver involved)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04921527 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF/VEGFR inhibitor, Aurora kinase inhibitor, taxane disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages